Expression of the soluble vascular endothelial growth factor receptor-1 in cutaneous melanoma: role in tumour progression - PubMed (original) (raw)

Expression of the soluble vascular endothelial growth factor receptor-1 in cutaneous melanoma: role in tumour progression

F Ruffini et al. Br J Dermatol. 2011 May.

Abstract

Background: Vascular endothelial growth factor (VEGF)-A, placenta growth factor (PlGF) and their corresponding membrane receptors are involved in autocrine and paracrine regulation of melanoma growth and metastasis. Besides the membrane receptors, a soluble form of the VEGF receptor (VEGFR)-1 (sVEGFR-1) has been identified, that behaves both as a decoy receptor, sequestering VEGF-A and PlGF, and as an extracellular matrix (ECM) molecule, promoting endothelial cell adhesion and migration through the interaction with α5β1 integrin.

Objectives: To analyse whether sVEGFR-1 plays a role during melanoma progression.

Methods: sVEGFR-1 expression was evaluated in a panel of 36 melanoma cell lines and 11 primary human melanocyte cultures by quantitative real-time polymerase chain reaction analysis and in specimens of primary or metastatic melanoma lesions from 23 patients by immunohistochemical analysis.

Results: sVEGFR-1 expression was highly upregulated in melanoma cell lines with respect to human melanocytes. Interestingly, cell lines obtained from cutaneous metastases showed a significant reduction of sVEGFR-1 expression, as compared with cell lines derived from primary tumours. These results were confirmed by immunohistochemical analysis of sections from primary skin melanomas and the corresponding cutaneous metastases, suggesting that modulation of sVEGFR-1 expression influences ECM invasion by melanoma cells and metastasis localization. Moreover, we provide evidence that adhesion of melanoma cells to sVEGFR-1 is favoured by the activation of a VEGF-A/VEGFR-2 autocrine loop.

Conclusions: Our data strongly suggest that sVEGFR-1 plays a role in melanoma progression and that low sVEGFR-1/VEGF-A and sVEGFR-1/transmembrane VEGFR-1 ratios might predict a poor outcome in patients with melanoma.

© 2011 The Authors. BJD © 2011 British Association of Dermatologists.

PubMed Disclaimer

Similar articles

• An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells.
  Lacal PM, Ruffini F, Pagani E, D'Atri S. Lacal PM, et al. Int J Oncol. 2005 Dec;27(6):1625-32. Int J Oncol. 2005. PMID: 16273219
• The role of vascular endothelial growth factors and their receptors in malignant melanomas.
  Brychtova S, Bezdekova M, Brychta T, Tichy M. Brychtova S, et al. Neoplasma. 2008;55(4):273-9. Neoplasma. 2008. PMID: 18505336
• The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.
  Hanrahan V, Currie MJ, Gunningham SP, Morrin HR, Scott PA, Robinson BA, Fox SB. Hanrahan V, et al. J Pathol. 2003 Jun;200(2):183-94. doi: 10.1002/path.1339. J Pathol. 2003. PMID: 12754739
• [Angiogenesis and tumor progression in melanoma].
  Vacca A, Ria R, Ribatti D, Bruno M, Dammacco F. Vacca A, et al. Recenti Prog Med. 2000 Nov;91(11):581-7. Recenti Prog Med. 2000. PMID: 11125952 Review. Italian.
• Melanoma inhibitory activity (MIA): an important molecule in melanoma development and progression.
  Bosserhoff AK. Bosserhoff AK. Pigment Cell Res. 2005 Dec;18(6):411-6. doi: 10.1111/j.1600-0749.2005.00274.x. Pigment Cell Res. 2005. PMID: 16280006 Review.

Cited by

• The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells.
  Atzori MG, Tentori L, Ruffini F, Ceci C, Lisi L, Bonanno E, Scimeca M, Eskilsson E, Daubon T, Miletic H, Ricci Vitiani L, Pallini R, Navarra P, Bjerkvig R, D'Atri S, Lacal PM, Graziani G. Atzori MG, et al. J Exp Clin Cancer Res. 2017 Aug 10;36(1):106. doi: 10.1186/s13046-017-0577-2. J Exp Clin Cancer Res. 2017. PMID: 28797294 Free PMC article.
• Positive and Negative Regulation of Angiogenesis by Soluble Vascular Endothelial Growth Factor Receptor-1.
  Failla CM, Carbo M, Morea V. Failla CM, et al. Int J Mol Sci. 2018 Apr 27;19(5):1306. doi: 10.3390/ijms19051306. Int J Mol Sci. 2018. PMID: 29702562 Free PMC article. Review.
• The sVEGFR1-i13 splice variant regulates a β1 integrin/VEGFR autocrine loop involved in the progression and the response to anti-angiogenic therapies of squamous cell lung carcinoma.
  Abou Faycal C, Brambilla E, Agorreta J, Lepeltier N, Jacquet T, Lemaître N, Emadali A, Lucas A, Lacal PM, Montuenga L, Pio R, Gazzeri S, Eymin B. Abou Faycal C, et al. Br J Cancer. 2018 Jun;118(12):1596-1608. doi: 10.1038/s41416-018-0128-4. Epub 2018 May 24. Br J Cancer. 2018. PMID: 29795310 Free PMC article.
• Hypoxia-dependent drivers of melanoma progression.
  D'Aguanno S, Mallone F, Marenco M, Del Bufalo D, Moramarco A. D'Aguanno S, et al. J Exp Clin Cancer Res. 2021 May 8;40(1):159. doi: 10.1186/s13046-021-01926-6. J Exp Clin Cancer Res. 2021. PMID: 33964953 Free PMC article. Review.
• Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding.
  Graziani G, Ruffini F, Tentori L, Scimeca M, Dorio AS, Atzori MG, Failla CM, Morea V, Bonanno E, D'Atri S, Lacal PM. Graziani G, et al. Oncotarget. 2016 Nov 8;7(45):72868-72885. doi: 10.18632/oncotarget.12108. Oncotarget. 2016. PMID: 27655684 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Silverchair Information Systems
  • Wiley

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information